Announcement • May 08
CDT Equity Inc. Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions CDT Equity Inc. announced that AZD5904, a potent inhibitor of human Myeloperoxidase, originally licensed from AstraZeneca, has progressed into the Patent Cooperation Treaty phase, marking a significant step in the globalisation of its intellectual property protection. AZD5904 benefits from an extensive clinical safety data package, with a total of 181 subjects dosed across five Phase 1 studies. The asset has demonstrated a favourable safety profile, with no overtly drug-related adverse events identified. The Company holds both a composition of matter patent and a method of use patent relating to AZD5904 in idiopathic male infertility, supported by pre-clinical data demonstrating its potential. The progression to Patent Cooperation Treaty stage enables CDT to pursue broader international protection, supporting the potential global development and commercialisation of the asset. CDT has identified promising signals for AZD5904 in idiopathic male infertility, as well as in related oncology-associated infertility markets. The Company is now actively seeking out-licensing and strategic partnering opportunities to advance AZD5904 into later-stage development. The Company intends to position the asset as a data-backed, clinically de-risked opportunity for pharmaceutical partners, with the potential to generate near-term and long-term value through structured licensing arrangements. Announcement • Apr 02
CDT Equity Inc. announced delayed annual 10-K filing On 04/01/2026, CDT Equity Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Announcement • Mar 27
CDT Equity Inc. Expands Tapinarof Intellectual Property Portfolio With Two New Patent Filings CDT Equity Inc. announced the filing of two new patent applications that further expand the Company’s intellectual property portfolio surrounding tapinarof, a drug currently approved for the treatment of psoriasis and atopic dermatitis. The first newly filed patent covers a combination therapy pairing tapinarof with a class of drugs clinically proven in psoriasis and atopic dermatitis, while the second patent relates to novel cocrystal forms of tapinarof with these agents. The combination approach may also enable entry into disease areas not previously addressable by tapinarof alone, supporting expansion of the addressable market and increasing the breadth of potential out-licensing opportunities. Following Organon’s $1,200 million acquisition of Dermavant in 2024, recent market trends suggest that second-generation products are increasingly well positioned to capture growing demand for novel topical therapies as alternatives to oral and injectable treatments for skin conditions. The combinations were identified following analysis conducted using the proprietary Signature Agent platform developed by Sarborg Limited. Through this process, CDT evaluated a large number of disease signatures and therapeutic relationships, enabling the identification of combinations that may improve outcomes in existing dermatological markets while also highlighting opportunities in additional conditions that remain underserved. Whilst tapinarof has demonstrated clinical efficacy in psoriasis and atopic dermatitis, Sarborg analysis indicates that these novel combinations may offer enhanced efficacy by synergistically targeting multiple disease pathways. The analysis also suggests potential applicability across several additional dermatological conditions, including orphan diseases with limited treatment options. The Company believes the continued expansion of its tapinarof intellectual property portfolio reinforces its strategy of combining artificial intelligence-driven analysis with targeted IP development around clinically validated compounds. CDT intends to pursue out-licensing opportunities with pharmaceutical companies and specialist partners seeking to advance differentiated assets in dermatology and related therapeutic areas. 
